Galaxy CCRO
Galaxy CCRO is dedicated to developing innovative blood test technologies for stroke detection and other medical applications. Founded by clinicians and scientists, the company aims to leverage under-exploited biomarkers and near-patient testing to improve diagnosis and treatment of ischemic stroke. They also work on early detection of severe manifestations of Covid-19 and develop rapid field tests for diseases like Chronic Wasting Disease in deer. Their mission is to serve human medical needs ethically and morally, with a focus on impactful medical breakthroughs for humanity.
Industries
Nr. of Employees
small (1-50)
Products
Bedside lateral flow stroke test (point-of-care GSTP test)
A bedside point-of-care lateral flow assay designed to measure a protein biomarker (GSTP) from a small blood sample to assist in stroke diagnosis and infer time of onset within minutes.
Field-deployable Chronic Wasting Disease (CWD) detection test
Planned rapid field test for detection of Chronic Wasting Disease in cervids using protein detection, tissue imaging, and AI-assisted interpretation for use during field dressing.
Bedside lateral flow stroke test (point-of-care GSTP test)
A bedside point-of-care lateral flow assay designed to measure a protein biomarker (GSTP) from a small blood sample to assist in stroke diagnosis and infer time of onset within minutes.
Field-deployable Chronic Wasting Disease (CWD) detection test
Planned rapid field test for detection of Chronic Wasting Disease in cervids using protein detection, tissue imaging, and AI-assisted interpretation for use during field dressing.
Services
Clinical research and development support for diagnostic programs, collaborating with clinicians and academic partners to advance biomarker-based tests.
Advisory services to refine, license, and commercialize diagnostic-related intellectual property and patents.
NDA-protected portals and controlled disclosure of confidential project details for investors and strategic partners.
Clinical research and development support for diagnostic programs, collaborating with clinicians and academic partners to advance biomarker-based tests.
Advisory services to refine, license, and commercialize diagnostic-related intellectual property and patents.
NDA-protected portals and controlled disclosure of confidential project details for investors and strategic partners.
Expertise Areas
- Point-of-care diagnostic development
- Protein biomarker discovery and validation
- Lateral flow assay design
- Stroke diagnostics and emergency care workflows
Key Technologies
- Lateral flow assays
- Protein biomarker assays
- Point-of-care testing
- Fingerstick blood sampling
News & Updates
Expansion into CWD detection
Galaxy CCRO announced the expansion of their clinical research projects to include a field test for Chronic Wasting Disease in deer and cervids.
COVID-19 research focus
The company is working on testing technology that can aid in early detection of severe Covid-19 manifestations.
Stroke diagnosis innovation
Galaxy CCRO is developing bedside blood tests for stroke to improve diagnosis and treatment outcomes.
The world is waiting for a blood test for stroke
Estimates indicate that 13.7 million people worldwide will have their first stroke this year, with 5.5 million deaths. The company aims to develop a blood test to improve diagnosis.
Stroke testing is our top priority
Galaxy CCRO focuses on developing bedside stroke detection methods to help clinicians make life-changing decisions quickly.
Covid-19 research and early detection
The company’s technology has potential to aid in early detection of severe Covid-19 manifestations.
Expansion into CWD detection
Galaxy CCRO announced the expansion of their clinical research projects to include a field test for Chronic Wasting Disease in deer and cervids.
COVID-19 research focus
The company is working on testing technology that can aid in early detection of severe Covid-19 manifestations.
Stroke diagnosis innovation
Galaxy CCRO is developing bedside blood tests for stroke to improve diagnosis and treatment outcomes.
The world is waiting for a blood test for stroke
Estimates indicate that 13.7 million people worldwide will have their first stroke this year, with 5.5 million deaths. The company aims to develop a blood test to improve diagnosis.
Stroke testing is our top priority
Galaxy CCRO focuses on developing bedside stroke detection methods to help clinicians make life-changing decisions quickly.
Covid-19 research and early detection
The company’s technology has potential to aid in early detection of severe Covid-19 manifestations.